Racial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Sept. 28, 2023 -- There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) in patients with type 2 diabetes, according to a review published online Sept. 21 in the Journal of the Royal Society of Medicine.
Setor K. Kunutsor, M.D., Ph.D., from University of Leicester in the United Kingdom, and colleagues conducted a systematic literature review and meta-analysis to compare racial/ethnic as well as regional pattern effects for SGLT2is and GLP1-RAs on cardiovascular disease (CVD) and renal outcomes in patients with type 2 diabetes.
Based on 14 included trials, the researchers found that the risk for major adverse cardiovascular events (MACE) varied with SGLT2is by race (White: hazard ratio [HR], 0.92; Asian: HR, 0.69; Hispanic/Latino: HR, 0.70) versus placebo. Similar results were seen for GLP1-RAs versus placebo (HRs, 0.88, 0.76, and 0.82, respectively). For other cardiorenal outcomes, SGLT2is reduced the risk in White and Asian populations, except for heart failure hospitalizations in Asians. There were no effects found in Black populations except for a reduced risk for heart failure hospitalizations by SGLT2i. The risk for composite CVD death/heart failure hospitalization was reduced with SGLT2-Is in North America and Europe, while GLP1-RAs cut the risk for MACE in Europe. Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) certainty of evidence ranged from moderate to high.
"Whether the differences are due to issues with underrepresentation of Black populations and low statistical power or racial/ethnic variations in the pharmacokinetics, pharmacodynamics, and safety of SGLT2-Is and GLP1-RAs needs further investigation," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Mortality in Rheumatic Heart Disease Is High
FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.